COST-UTILITY ANALYSIS AND EFFICIENCY FRONTIER APPROACH OF TAFASITAMAB IN BRAZILIAN PRIVATE HEALTHCARE SYSTEM PERSPECTIVE

被引：0
|
作者：
Fahham, L. [1 ]
Dias, L. [2 ]
Amaral, L. Murta [2 ]
Mazzuco, C. [3 ]
Araujo, G. [3 ]
机构：
[1] ORIGIN Hlth, Sao Paulo, Brazil
[2] ORIGIN Hlth, Rio De Janeiro, RJ, Brazil
[3] Knight Therapeut, Sao Paulo, SP, Brazil
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE442
引用
收藏
页数：2
相关论文
共 50 条
  • [1] COST-UTILITY OF BELIMUMAB IN TREATING LUPUS NEPHRITIS: A BRAZILIAN PRIVATE HEALTHCARE SYSTEM PERSPECTIVE
    Silva, D.
    Marchesan, T.
    Araujo, M.
    Tanaka, S.
    Bernardino, G.
    VALUE IN HEALTH, 2024, 27 (06) : S93 - S93
  • [2] Cost-utility Analysis of Opportunistic and Systematic Diabetic Retinopathy Screening Strategies from the Perspective of the Brazilian Public Healthcare System
    Ben, Angela J.
    Neyeloff, Jeruza L.
    de Souza, Camila F.
    Rosses, Ana Paula O.
    de Araujo, Aline L.
    Szortika, Adriana
    Locatelli, Franciele
    de Carvalho, Gabriela
    Neumann, Cristina R.
    APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2020, 18 (01) : 57 - 68
  • [3] Cost-utility Analysis of Opportunistic and Systematic Diabetic Retinopathy Screening Strategies from the Perspective of the Brazilian Public Healthcare System
    Ângela J. Ben
    Jeruza L. Neyeloff
    Camila F. de Souza
    Ana Paula O. Rosses
    Aline L. de Araujo
    Adriana Szortika
    Franciele Locatelli
    Gabriela de Carvalho
    Cristina R. Neumann
    Applied Health Economics and Health Policy, 2020, 18 : 57 - 68
  • [4] Cost-Utility Analysis of Deep Brain Stimulation for Generalized and Cervical Dystonia: A Perspective from Brazilian Healthcare
    Nardi, Elene Paltrinieri
    Silva, Lucas Caetano Araujo
    Kawakami, Daniele Yukari
    Nonato, Isis Nalin Fernandes
    Biase, Tayanny Margarida Menezes Almeida
    Fernandes, Ricardo Ribeiro Alves
    de Melo, Daniela Oliveira
    WORLD NEUROSURGERY, 2024, 191 : E438 - E464
  • [5] Cost-utility analysis of duloxetine in osteoarthritis: A US private payer perspective
    Wielage R.C.
    Bansal M.
    Andrews J.S.
    Klein R.W.
    Happich M.
    Applied Health Economics and Health Policy, 2013, 11 (3) : 219 - 236
  • [6] Cost-utility analysis of duloxetine in osteoarthritis: from Chinese healthcare perspective
    Sun, Xueshan
    Zhen, Xuemei
    Gu, Shuyan
    Liu, Kaijie
    Yang, Wenqianzi
    Dong, Hengjin
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2025, 25 (02) : 245 - 256
  • [7] COST-UTILITY ANALYSIS OF INFLUENZA VACCINATION WITH A HIGH DOSE QUADRIVALENT VACCINE FOR THE BRAZILIAN ELDERLY POPULATION IN THE PRIVATE HEALTHCARE SECTOR
    Watanabe, S. F.
    Richtmann, R.
    Moraes, J. C.
    Ribeiro, Antonini R.
    Galvao, E.
    de Courville, C.
    Ribeiro, K.
    Santoro, J.
    VALUE IN HEALTH, 2023, 26 (12) : S371 - S371
  • [8] Comment on: "Cost-Utility Analysis of Duloxetine in Osteoarthritis: A US Private Payer Perspective''
    Liedgens, Hiltrud
    Henske, Rainer
    APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2013, 11 (05) : 553 - 554
  • [9] Comment on: “Cost-Utility Analysis of Duloxetine in Osteoarthritis: A US Private Payer Perspective”
    Hiltrud Liedgens
    Rainer Henske
    Applied Health Economics and Health Policy, 2013, 11 (5) : 553 - 554
  • [10] Cost-utility analysis from a societal perspective
    Johannesson, M
    OConor, RM
    HEALTH POLICY, 1997, 39 (03) : 241 - 253
12345